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ABSTRACT: P53 expression was assessed in 93 head and neck squamous cell carcinoma patients using CM-1, 
DO-7, and DO-1 antibodies. Sixty eight percent was found to have positive nuclear staining. The frequency of p53 
mutations were investigated in 13 patients using single-stranded conformational polymorphism (SSCP) analysis 
of DNA fragments that had been amplified by the polymerase chain reaction (PCR). P53 gene mutations were 
analyzed by SSCP in exons 4 to 7 of 13 patients, and nine were found to have mutations in exon 4; two of these 
patients also had a mutation in exon 5. In the group of 93 patients, p53 overexpression was found to correlate with 
the patients' history of heavy smoking (p <0.01). We also analyzed the drinking and smoking history of 71 of these 
patients by logistic regression analysis and found that heavy smoking correlates with p53 overexpression (p <0.05), 
but heavy drinking was not found to be significant. However when both smoking and drinking histories were 
assessed together, a correlation was found (p <0.05). Future work may indicate that specific p53 mutations are 
associated with patients who have a history of heavy drinking and smoking. 
KEYWORDS: p53 tumor suppressor gene, expression, mutations (SSCP), head and neck cancer, smoking, 
drinking, survival. 
I. INTRODUCTION 
Squamous cell carcinoma of the head and 
neck accounts for about 2% of all solid malignan-
cies in the Western world. However, it is one of 
the most distressing diseases because its surgical 
treatment often results in dysfunction and disfig-
urement.1 Furthermore, the success of treating 
this disease has not improved in the last 25 years.2 
Molecular investigations into head and neck can-
cer were started in the last 8 years, and now a 
number of oncogenes, ras, myc erbB-l, and the 
p53 tumor suppressor gene, have been implicated 
in the development of this disease.3 
Initial investigations into p53 head and neck 
cancer indicated that about 60% of these cancers 
overexpressed this gene4-8 but no correlations 
have been found between p53 overexpression 
and any of the clinicopathological parameters.4 
In addition, p53 mutations have been demon-
strated by single-stranded conformational poly-
morphism (SSCP) analysis and sequencing in a 
range of head and neck tumor specimens and cell 
lines.6·9"13 
The p53 gene product was initially identified 
as a host cell protein bound to the large T-antigen, 
the dominant transforming oncogene of the SV40 
virus.14 Normal levels of p53 act as tumor sup-
pressor genes, but mutations in the p53 gene may 
convert it into a dominant gene. However, they 
may remain as recessive or become null 
mutations.15·16 Inactivation of the p53 gene may 
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also be caused by deletions,17 binding to viral 
oncoproteins,18 or by binding to host proteins.19 A 
turning point in our understanding of this tumor 
suppressor gene occurred with the publications of 
Oliner et al.,19 Farmer et al.,20 and Yin et al.,21 
which has led to the recently proposed models for 
p53 function.21-23 There is overwhelming epide­
miological evidence for a correlation between 
heavy smoking and drinking in head and neck 
cancer.
24-27
 However, there is little genetic infor­
mation available that links exposure of tobacco 
and alcohol to head and neck cancer. The aim of 
this study was to assess the level of p53 expres­
sion and mutations in head and neck cancer pa­
tients and correlate the results with a range of 
clinicopathological parameters and with the pa­
tients' tobacco and alcohol usage. 
II. MATERIALS AND METHODS 
A. Tumor Specimens and Patient Details 
Ninety-three patients with squamous cell car­
cinoma of the head and neck (oral, laryngeal, 
pharyngeal, and nodal specimens) were selected 
for this study from the Department of Otorhino-
laryngology, University of Liverpool. Tumor tis­
sue samples obtained from surgical specimens 
were frozen in liquid nitrogen. The tissue sections 
used in the immunohistochemical investigations 
in this study had been fixed in formalin and em­
bedded in paraffin wax. Serial sections of 5 μπι 
thickness were cut and processed for immunohis-
tochemistry. The following clinicopathological 
data were available: sex, age, site of primary tu­
mor, TNM staging using the UICC28 convention, 
site of recurrence, histopathological differentia­
tion, the pathology of lymph node metastasis, and 
follow-up. The smoking pattern was classified as 
nonsmokers, moderate smokers (under 20 ciga­
rettes per day), and heavy smokers (over 20 ciga­
rettes per day) or equivalent quantities of pipe 
tobacco. Patients who had stopped smoking for 
more than 5 years were also considered sepa­
rately. The patients' drinking history was also 
recorded: nondrinker, moderate drinker (less than 
21 units per week), and heavy drinker (over 21 
units per week). 
Also, a group of patients with benign and 
potentially malignant head and neck lesions were 
included in this study. These included fibromas, 
keratosis, hyperkeratosis, leukoplakias, and speci­
mens of normal tissues. 
B. DNA Extraction 
Genomic DNA was extracted from the tumor 
specimens by methods previously described.29 
C. PCR-SSCP Analysis 
The primers for the p53 gene containing ex-
ons 4 to 9 (2.9 kb) were amplified by the poly­
merase chain reaction (PCR) using the primers in 
Table I. The PCR reaction (50 μΐ) contained 250 ng 
of genomic DNA, 0.4 μΜ of each respective 
primer, 2.5 units of Taq polymerase, 5 μΐ of 10X 
PCR buffer (100 mM Tris-HCL pH 8.3), and 
0.2 mM dNTP mixture. The reactions were ini­
tially denaturated at 98°C for 7 min and then 
allowed to cool to 90°C. The Taq polymerase was 
then added to the samples and the samples placed 
in a thermocycler. The DNA was amplified for 30 
cycles consisting of 95°C for 1 min, 58°C for 
1 min, and 70°C for 4 min. Five microliters of 
PCR samples were analyzed by electrophoresis 
on a 0.8% ultrapure agarose gel (BRL, U.S.) and 
the amplified products visualized under UV light 
after staining with ethidium bromide. 
D. Nested PCR-SSCP Analysis 
One microliter of each sample's first PCR 
reaction mixture (amplified DNA size, 2.9 kb) 
was combined with 5 μΐ of 10X PCR buffer, 
1 μ α [a-32P]dCTP (3000 Ci/mmol; Amersham, 
U.K.), 1 μΐ dNTP mixture (0.2 mM dATP, 
0.02 mM dCTP, 0.2 mM dGTP, and 0.2 mM 
dl IP), and 0.4 μΜ of both primers for a specific 
exon in a final volume of 50 μΐ (Table I). After an 
initial denaturation step at 98°C for 5 min, 2.5 
units of Taq polymerase were added to each reac­
tion tube, which was then placed in the 
thermocycler for 30 cycles. The temperatures and 
times for the reaction cycles of exons 4,5, 6, and 
7 were 95°C (25 s), 62°C (25 s), and 70°C (30 s), 
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TABLE 1 
Primers for PCR Amplification 
Amplified 
gene 
p53 
Exon 4-9 
Exon 4 
Exon 5 
Exon 6 
Exon 7 
Primer sequence 
5'-GTAGGAATTCGTCCCAAGCAATGGATGAT-3' 
S'-CATCGAATTCTGGAAACTTTCCACCTTGAT-S' 
Primers for p53 exons 4-9 - PCR - SSCP 
PU4: 5'-AATGGATGATTGATGCTGTCC-3' 
PD4: 5'-CTCAGGGCAACTGACCGTGC-3' 
PU5: 5'-GACTTTCAACTGTCTC-3' 
PD5; 5'-CTGGGACCCTGGGCAAC-3' 
PU6: 5'-GAGACGACAGGGCTGGTT-3' 
PD6: 5'CCACTGACAACCACCCTT-3' 
PU7: 5'-GTGTTGTCTCCTAGGTTGGC-3' 
PD7: 5'-AAGTGGCTCCTGACCTGGAG-3' 
(sense) 
(antisense) 
(sense) 
(antisense) 
(sense) 
(antisense) 
(sense) 
(antisense) 
(sense) 
(antisense) 
respectively. Five microliters of the PCR-ampli-
fied product was then diluted with 40 μΐ of buffer 
A (0.1% SDS, 10 mM EDTA), and 5 μΐ of this 
mixture was added to an equal volume of stop 
solution (95% formamide, 20 mM EDTA, 0.05% 
bromophenol blue, and 0.05% xylene cyanol) 
(United States Biochemicals, Ohio). Samples 
were denaturated at 98°C for 7 min and placed 
immediately on ice to prevent renaturation be­
fore being run on 1 mm χ 20 x 24 cm, 0.6X 
hydrolink Polyacrylamide nondenaturing gels. 
The DNA was electrophoresed in TBE (0.09 M 
Tris base, 0.09 boric acid, and 2.5 mM EDTA) 
running buffer at 12 to 15 W at room tempera­
ture. Gels were dried and exposed to XAR-5 
film (Kodak) for 12 to 24 h. 
E. Immunohistochemical Analysis 
Immunohistochemical analysis of the p53 
protein was undertaken using the CM-1 antibody 
in all cases;30 DO-7 and DO-1 antibodies were 
used in the majority of the cases.31 The rabbit 
antiserum CM-1 has been raised against full-length 
p53 expressed in Escherichia coli using a modi­
fied T7-based expression vector such that the first 
methionine of p53 was the initiation codon. This 
resulted in an expression vector that encodes a 
full-length p53 protein that is not fused to any 
other protein sequences.30 The CM-1 antibody 
was used at a concentration of 1 in 50, and DO-7 
was used at 1 in 100. The DO-1 and DO-7 anti­
bodies were prepared from splenotypes from 
BALB/c mice, hyperimmunized with recombi­
nant human wild-type protein, and fused with a 
nonproducing mouse myeloma cell line.31 The 
DO-1 antibody was kindly provided by Professor 
D. Lane and used at a 1 in 100 dilution of culture 
supernatant. The avidin-biotin (ABC) technique 
was used to stain the paraffin-embedded sections. 
In negative controls, p53 CM-1, DO-7, and DO-1 
were omitted from the first stage and replaced 
with the same concentration of a polyclonal mouse 
immunoglobin (Sigma, Pool). Three cell lines were 
used as controls for p53 staining: spontaneously 
immortalized rat 208F cells were used as negative 
controls; positive controls included the MCF-7 
human breast cancer cell line and their transfected 
derivative RFV53H06-3 cells, which carry the 
mutant mouse p53 gene carrying valine instead of 
alanine at amino acid 135.32 P53 staining was 
scored as (1) negative or equivocal, (2) moderate, 
and (3) intense staining. 
F. Statistical Analysis 
Quantitative data were analyzed by χ2 or 
Fisher's exact test and weighted logistic regression 
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analysis33 where appropriate. Survival curves were 
drawn up using the Kaplan-Meier product limit 
estimate.34 Differences between survival times 
were analyzed by the log rank method.35 
III. RESULTS 
Ninety-three head and neck cancer patients 
were assessed for p53 levels of expression using 
a combination of antibodies (CM-1, DO-7, and 
DO-1). Sixty-eight percent of the specimens were 
found to have positive nuclear staining and 17% 
had intense staining. No correlations were found 
between p53 staining and age, sex, site of the 
primary tumor, tumor stage, or site of the recur­
rence. Neither was any correlation found between 
p53 expression and survival when calculated from 
the date of diagnosis of the disease (Figure 1). 
Thirteen of these patients were analyzed for 
mutations in exons 4 to 7, as the majority of 
previous studies have shown that the mutations in 
human tumors are found in this region.36 We first 
determined the optimal conditions for PCR am­
plification of the 2.9-kb p53 gene fragment (Fig­
ure 2) and for the nested PCR amplification of the 
individual exons, 4 to 7 (Figure 3). In order to 
exclude mutations caused by Taq polymerase, the 
SSCP analysis was carried out on two different 
occasions for each tumor sample. The SSCP re­
sults are shown in Figures 4 and 5. Nine of the 13 
tumor samples investigated showed extra bands, 
which indicates the presence of mutations. The 
same fragment as the wild-type control was also 
observed in the mutated specimens at varying 
intensities. This is due to the fact that the tumor 
specimens contain both normal and neoplastic 
cells. Nine of the p53 mutations were found in 
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FIGURE 1. Survival curve of 93 head and neck squamous cell carcinoma patients with positive and 
negative p53 expression, drawn up using the Kaplan-Meier product limit estimate. 
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2.9 Kb 
FIGURE 2. The 2.9-kb p53 gene fragment generated 
by PCR amplification. Lane 1, λ-DNA/Hindlll size mark­
ers; lanes 2 to 11,2.9-kb p53 gene fragment generated 
after 30 cycles of PCR using DNA from patients with 
squamous cell carcinoma of the head and neck. Elec­
trophoresis was on 0.8% agarose gel in 0.5X TBE 
buffer. 
exon 4 (tumor numbers 1, 5, 6, 7, 9, 10, 11, 12, 
and 13). However, two of these tumors also had 
a mutation in exon 5 (1, 5). No mutations were 
found in exons 6 or 7 (data not shown). All but 
one of the 13 patients analyzed for p53 mutations 
by SSCP analysis were found to overexpress p53. 
One patient with negative p53 staining was found 
to have a mutation in exon 4 and, furthermore, 
was a nonsmoker. 
In an ongoing study of smoking and p53 
levels of expression, we have demonstrated in 
this group of 93 patients that there is a signifi­
cant difference between p53 expression in non-
smokers and heavy smokers (p <0.01) (Table II). 
It is of note that 10 of 12 patients, who have 
stopped smoking for 5 years or more, overexpress 
p53. These data include 73 patients who have 
been previously reported by us.4 In this study, 
we also investigated the patients' drinking his­
tory, and the data were available on 81 of these 
patients. We analyzed the smoking and drinking 
history of these 72 patients by logistic regression 
analysis by two methods: (1) excluding those 
patients with a "stopped-smoking" history and (2) 
including this group of stopped-smoking patients. 
The analysis of the smoking and drinking history 
of the 63 patients (excluding the stopped-smok­
ing group) by logistic regression analysis demon­
strated that heavy smoking correlates with p53 
overexpression (Z = 2.01; ρ <0.05), but heavy 
drinking was not found to be significant (Z = 0.5; 
ρ >0.05). However, when both smoking and drink­
ing histories were assessed together, a correlation 
was found (Z = 2.15; ρ <0.05), which indicates 
that these two environmental factors are probably 
linked to aberrant expression of p53 in the etiol­
ogy of head and neck cancer (Figure 6). The 
analysis of the smoking and drinking history of 
the 72 patients (including the stopped-smoking 
group with the heavy smokers) indicated a corre­
lation between smoking and drinking (Z = 2.29; 
ρ <0.05). 
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FIGURE 3. The p53 gene exon fragments generated 
by nested PCR amplification. Lane 1, pBR322/Haelll/ 
BAP size markers; lane 2, exon 9; lane 3, exon 7; lane 
4, exon 6; lane 5, exon 5; lane 6, exon 4. The exons of 
the p53 gene were generated after 30 cycles of nested 
PCR using the 2.9-kb fragment as template. Electro­
phoresis was on 2% agarose gel in 0.5X TBE buffer. 
A group of patients who have had biopsies for 
benign and potentially malignant head and neck 
lesions were also analyzed for p53 levels of ex­
pression (i.e., fibromas, keratosis, hyperkeratosis, 
and leukoplakias). None of these biopsies or nor­
mal specimens was found to overexpress the p53 
protein. 
IV. DISCUSSION 
The role of p53 in the development of human 
cancers has now been demonstrated in a wide 
range of tumors;36 however, the stage at which 
p53 has its effect on the initiation or progression 
of the disease remains unclear. A number of re­
ports have considered this to be a late event in the 
development of colonic cancer,37·38 breast can­
cer,
39-41
 and lung cancer.42·43 However, Chiba et 
al.44 considered that mutations in the p53 gene 
occurred frequently in the early stages of non-
small-cell lung cancers. We have previously ar­
gued that because the stopped-smoking group of 
head and neck cancer patients were found to have 
high levels of p53 expression, alterations in this 
gene may be one of the early events in the devel­
opment of head and neck cancer.4 The updated 
data on smoking history and the stopped-smoking 
groups in this paper continue to support this hy­
pothesis. It is of particular note that Suzuki et al.45 
have recently demonstrated a statistical correla­
tion between p53 mutations and lifetime cigarette 
consumption in non-small-cell lung cancer pa­
tients in Japan. 
A number of research groups have analyzed 
p53 mutations in head and neck squamous cell 
carcinomas from patients in the U.S.," Japan,9 
Italy,10 and the U.K.6·46 All these groups except 
that of Brachman et al. ' ' have confined their analy­
sis of the p53 gene to exons 5 to 8, a region 
previously shown to contain the majority of p53 
mutations in squamous cell carcinomas from other 
anatomical sites. However, we have found a com­
pletely different pattern of mutations in the head 
and neck cancers from patients living in the north­
west of England. All of the tumors that showed a 
p53 mutation by SSCP analysis in our study were 
found in exon 4, except for two tumors that also 
had mutations in exon 5. Sequencing of exon 4 in 
these tumors has presently been undertaken to 
determine if these mutations are biologically sig­
nificant; and, as polymorphisms in certain exons 
have been previously reported, this possibility 
has to be excluded.47·48 On analyzing the p53 exon 
regions, where mutations have been reported in 
different parts of the world, no consensus emerges: 
the majority of the mutations in the U.S. are found 
in exon 7,11·12 whereas exons 5 and 8 are the most 
common in Japan,9·13 and exon 4 in the U.K. No 
pattern emerged from the Italian study1 0 
(Table ΙΠ). Furthermore, on examination of the 
nucleotide trans version pattern of these p53 
mutations in head and neck cancer patients, again 
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FIGURE 4. SSCP analysis of exon 4 of the p53 gene of the head and neck cancer 
specimens. An aliquot of the PCR amplified and ^P-labeled samples were loaded on 0.6X 
hydrolink Polyacrylamide nondenaturing gel. The DNA was electrophoresed according to 
the conditions described in Section II. (A) DNA from patient 1 (lane 1) shows one additional 
band (solid arrow), while DNA from patient 5 (lane 9) shows altered mobility (open arrow) 
compared with normal control DNA samples (lanes 2, 4, 6, 8, 10); (B) DNA from patients 
6, 7, 9,10,11,12, and 13 (lanes 1, 3, 7, 9,11,13, and 15) show one additional band (solid 
arrow) compared with normal control DNA samples (lanes 2, 4, 6, 8, 10, 12, 14, and 16) 
(open arrows). T, tumor; N, normal. 
no consensus emerges. In the U.S., Somers et al.12 
found that 63% (7/11) of tumors had G-T 
transversions, whereas Sakai et al.13 reported that 
50% of their specimens in Japan had G-A 
transversions. Because the type of mutation is 
often associated with specific mutagens, it would 
appear that there are particular carcinogens in 
different parts of the world causing similar can-
cers of the head and neck. This may be explained 
by the presence of regionally distinct carcinogens 
in both tobacco and alcohol interacting with local 
environmental cofactors in the development of 
this disease. 
The SSCP method for analysis of p53 muta-
tions has also been used to examine p53 muta-
tions in oral squamous cell carcinomas,13 where 
63% of the tumors were found to have mutations 
in the region of the p53 gene assessed (i.e., ex-
ons 5 to 8). We found a similar figure (60%) in 
the group of patients analyzed by SSCP (exons 
4 to 7). However, it is most likely that all re-
search groups to date are missing mutations by 
confining their investigations to specific regions 
of the p53 gene. In the future, it will be neces-
sary to analyze all the p53 exons by SSCP and 
confirm the results by sequencing to determine 
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FIGURE 4B 
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FIGURE 5. SSCP analysis of exon 5 of the p53 gene of the head and neck cancer 
specimens. DNA from patients 1 and 5 (lanes 1 and 9) show one additional band (solid 
arrow) compared with normal tissue samples (open arrows) (lanes 2, 4, 6, 8, and 10). 
the complete picture; we are currently pursuing 
this approach. 
In addition, a comparison of the p53 expres-
sion data with the site of the mutation will provide 
further insight into the mechanisms of the role of 
the p53 gene in the disease. Bodner et al.49 very 
elegantly demonstrated that the expression of the 
p53 protein in lung cancer patients correlates with 
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TABLE II 
P53 Expression and Smoking History 
in 93 Patients with Squamous Cell 
Carcinoma of the Head and Neck 
Smoking history 
Nonsmoker 
Stopped smoking 
>5 years 
Moderate smoker 
Heavy smoker 
Total 
p53 expression" 
-
8 
2 
11 
9 
30 
+ ++ 
4 0 
7 3 
10 3 
26 10 
47 16 
Note: Fishers Exact Test: nonsmoker and 
heavy smoker (p <0.01); stopped 
smoker and heavy smoker (p >0.05). 
a
 Moderate smoker, <20 cigarettes per day; 
heavy smoker, >20 cigarettes per day; 
stopped smoking, 5 to 18 years before 
developing a head and neck cancer. 
n S n D n S h D m S n D m S h D h S n D hShD 
nSmD nSmD hSmD 
0 p 5 3 n e g . B p 5 3 p o s ( + ) 
FIGURE 6. p53 overexpression correlates with the patients' history of heavy 
drinking and heavy smoking (Z = 2.15; ρ <0.05). nSnD = nonsmoker, nondrinker, 
etc. 
the class of the gene mutation. All the positively 
staining tumors were shown to have mutations in 
exons 5 to 8, whereas the negative-staining tumors 
were shown to have mutations outside these ex­
ons. These authors argued that the high-expressor 
group may represent the expression pattern of the 
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TABLE III 
p53 Mutations in Head and Neck Cancer Classified by Exon and 
Geographic Region 
Geographic 
region 
U.S. 
U.S. 
Japan 
Japan 
Italy 
U.K. 
U.K. 
2 
-
NT 
NT 
NT 
NT 
NT 
NT 
3 
NT 
NT 
NT 
NT 
NT 
NT 
4 
NT 
NT 
NT 
NT 
NT 
9 
5 
4 
2 
1 
7 
1 
1 
2 
|J«SW c 
6 
5 
1 
4 
— 
2 
NT 
— 
A U I I S 
7 
4 
6 
4 
— 
2 
1 
— 
t 
8 
2 
2 
5 
5 
1 
NT 
NT 
9 
1 
NT 
NT 
NT 
NT 
NT 
NT 
10 
NT 
NT 
NT 
NT 
NT 
NT 
11 
— 
NT 
NT 
NT 
NT 
NT 
NT 
Ref. 
11 
12 
9 
13 
10 
6 
This study 
dominant negative mechanism of p53 inactiva-
tion, whereas the low-expressor group may rep-
resent the expression of a recessive mechanism 
of inactivation of the p53 gene. Alternatively, 
these two expressor classes may represent mu-
tations caused by different groups of mutagens, 
and thus the p53 overexpressor group in the 
head and neck patients reported in this study, 
which correlates with the smoking and drinking 
history, may represent the activity of specific 
mutagens in the disease process. 
In this investigation, no correlations were 
found between p53 overexpression and any of 
the clinicopathological parameters, and this is 
the largest study reported to date in head and 
neck cancer. Furthermore, no correlation has 
been reported between p53 expression and sur-
vival in this group of patients. However, in an 
investigation into p53 expression in "end-stage 
disease" in squamous cell carcinoma of the head 
and neck, we have shown that there is a corre-
lation between p53 overexpression and a worse 
clinical outcome, indicating that p53 may also 
play a role in the late stages of the disease 
process.50 
Investigations into the role of the p53 tu-
mor suppressor gene in the pathogenesis of 
cancer has shown that this gene plays a number 
of diverse roles in the development of the dis-
ease.20·21·51-53 It is now apparent that p53 may 
also have a number of roles in the development 
of head and neck cancer based on the previ-
ously described results — the relationship be-
tween p53 expression in the stopped-smoking 
group of patients and the correlation between 
survival and end-stage disease.48·54 
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